OrigAMI-2: Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Cancer

Condition: Colorectal Cancer

Sponsor: Janssen Research & Development, LLC

Full Title
Protocol 61186372COR3001: A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Study Treatment
EGFRxMET bispecific antibody Amivantamab vs Cetuximab
Given in combination with either FOLFOX or FOLFIRI chemotherapy

Eligibility/Info
KRAS, NRAS, and BRAF wild type unresectable or metastatic left sided colorectal cancer that has not previously been treated with systemic therapy in the metastatic setting.

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage